Jason Butler
Stock Analyst at JMP Securities
(2.21)
# 2,588
Out of 4,829 analysts
139
Total ratings
36.5%
Success rate
-3.68%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $80 → $78 | $7.43 | +949.80% | 9 | May 9, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $71.04 | +40.77% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $12.39 | +206.70% | 8 | May 7, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.68 | +394.01% | 3 | Apr 30, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $31.70 | +146.10% | 16 | Apr 10, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Market Outperform | $28 | $10.23 | +173.70% | 1 | Apr 8, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.33 | +351.13% | 9 | Mar 20, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $7.87 | +128.72% | 2 | Mar 12, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $4 | $0.80 | +401.13% | 7 | Mar 5, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $696 → $701 | $549.27 | +27.62% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $9.41 | +250.69% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.70 | +143.24% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $22 | $2.46 | +794.31% | 4 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $65.87 | +10.82% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.79 | +222.58% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $10.38 | +275.72% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.25 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.30 | +1,669.23% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.66 | +62.95% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $17.44 | +123.62% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.71 | +3,002.09% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.61 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $6.23 | +674,057.30% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $5.27 | +2,101.14% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.23 | +178.64% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.29 | - | 1 | Dec 2, 2020 |
Prothena Corporation
May 9, 2025
Maintains: Market Outperform
Price Target: $80 → $78
Current: $7.43
Upside: +949.80%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $71.04
Upside: +40.77%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $12.39
Upside: +206.70%
ABIVAX Société Anonyme
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.68
Upside: +394.01%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $31.70
Upside: +146.10%
Rapport Therapeutics
Apr 8, 2025
Initiates: Market Outperform
Price Target: $28
Current: $10.23
Upside: +173.70%
Precigen
Mar 20, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.33
Upside: +351.13%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $7.87
Upside: +128.72%
Esperion Therapeutics
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.80
Upside: +401.13%
argenx SE
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $549.27
Upside: +27.62%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $9.41
Upside: +250.69%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.70
Upside: +143.24%
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $2.46
Upside: +794.31%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $65.87
Upside: +10.82%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.79
Upside: +222.58%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $10.38
Upside: +275.72%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.25
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.30
Upside: +1,669.23%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.66
Upside: +62.95%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $17.44
Upside: +123.62%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.71
Upside: +3,002.09%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.61
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $6.23
Upside: +674,057.30%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $5.27
Upside: +2,101.14%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.23
Upside: +178.64%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.29
Upside: -